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Background: The inhibitor of differentiation (ID) genes have been implicated as promoters of tumor progression
and metastasis in many human cancers. The current study investigated the expression and functional roles of ID
genes in seeding and prognosis of medulloblastoma.
Methods: ID gene expression was screened in human medulloblastoma tissues. Knockdown of ID3 gene was
performed in medulloblastoma cells in vitro. The expression of metastasis-related genes after ID3 knockdown was
assessed. The effect of ID3 knockdown on tumor seeding was observed in an animal model in vivo. The survival of
medulloblastoma patients was plotted according to the ID3 expression levels.
Results: Significantly higher ID3 expression was observed in medulloblastoma with cerebrospinal fluid seeding than
tumors without seeding. Knockdown of ID3 decreased proliferation, increased apoptosis, and suppressed the
migration of D283 medulloblastoma cells in vitro. In a seeding model of medulloblastoma, ID3 knockdown in vivo
with shRNA inhibited the growth of primary tumors, prevented the development of leptomeningeal seeding, and
prolonged animal survival. High ID3 expression was associated with shorter survival of medulloblastoma patients,
especially in Group 4 medulloblastomas.
Conclusions: High ID3 expression is associated with medullolbastoma seeding and is a poor prognostic factor,
especially in patients with Group 4 tumors. ID3 may represent the metastatic/ aggressive phenotype of a subgroup
of medulloblastoma.
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Medulloblastoma is an aggressive neoplasm developing
in the cerebellum of children. Long-term survival rates
of children with medulloblastoma have increased since
1980s with adoption of whole neuraxis irradiation and
chemotherapy [1,2]. However, a substantial portion of
patients still have a grim prognosis despite intensified
therapies. Poor prognostic factors of newly diagnosed
medulloblastomas are well known in large clinical trials:
a young age of onset (< 3 yrs), a large residual tumor
after surgery, tumor dissemination (seeding) into the
cerebrospinal fluid (CSF), and possibly an anaplastic/* Correspondence: nsthomas@snu.ac.kr
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reproduction in any medium, provided the orlarge cell histology [3-5]. Among these clinical factors,
tumor seeding at presentation may have the strongest
impact on patient prognosis, as described in many stud-
ies [6,7].
Our previous study on medulloblastoma demonstrated
that patients with tumor seeding at presentation had a
5-year survival rate of 38% in contrast to 73% for pa-
tients without tumor seeding [8]. Although both medul-
loblastoma and glioma are intra-axial tumors, their
patterns of dissemination are quite different. Medullo-
blastoma frequently ‘seeds’ through the CSF pathway
into spinal and intracranial subarachnoid spaces, but gli-
omas usually infiltrate white matter tracts that are adja-
cent to the primary tumor [9,10]. Large-scale genomic
analyses revealed the multiple origins and molecular
pathogenesis of medulloblastoma [11-14]. Recently, sev-
eral studies have been focused on the mechanism of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of the phenomenon may lead to dramatic therapeutic
improvement. Researchers in Toronto revealed that
metastatic cells of medulloblastoma have distinct genetic
variations and identified some candidate genes related to
medulloblastoma seeding through functional genomics
[15,16]. Furthermore, downstream targets of MYC onco-
gene and tumor-promoting microRNAs have also been
implicated as drivers of medulloblastoma dissemination
[17,18]. However, as medulloblastoma has diverse patho-
genetic origins, many different genes may function as
key metastasis-promoting genes in subgroups of pa-
tients. Therefore, it may be important to search for can-
didate genes using human medulloblastoma tissues.
Inhibitor of differentiation (ID) genes encode tran-
scription factors with a basic helix-loop-helix (bHLH)
motif that act as suppressors of cellular differentiation
[19,20]. ID molecules are involved in a wide range of cel-
lular processes such as cell proliferation and migration.
Interestingly, ID genes are overexpressed in many hu-
man cancers of epithelial origin, such as esophageal,
pancreatic, colorectal, prostate, and breast cancer
[21-25]. ID genes promote tumor cell migration, inva-
sion, and angiogenesis which are key components of
tumor metastasis [19,26]. Therefore, ID genes are poten-
tial metastasis-promoting genes that confer aggressive-
ness to epithelial tumors. Therefore, ID genes could be
candidate genes for human medulloblastoma seeding.
This study investigated the expression of ID genes in
human medulloblastoma and demonstrated that ID3
overexpression was significantly associated with tumor
seeding and poor prognosis of the patients. In vitro and
in vivo studies demonstrated that the ID3 gene partici-
pated in suppression of apoptosis and the migration of
medulloblastoma cells. Interestingly, a subgroup of me-
dulloblastoma, Group 4 tumors showed significantly
higher ID3 expression than the other subgroups. High
ID3 expression was a poor prognostic factor, especially
in patients with Group 4 tumors. ID3 may represent the
metastatic/ aggressive phenotype of a subgroup of
medulloblastoma.
Methods
Tumor tissues and cell lines
All studies reported here were performed with approval
of the Institutional Review Board of the Seoul National
University Hospital. Snap-frozen medulloblastoma tissue
from 39 patients was retrieved from the Brain Bank of
the Division of Pediatric Neurosurgery, Seoul National
University Children’s Hospital. Normal cerebellar tissue
was retrieved from the same tissue bank for use as a
control. Patient selection was based on the availability of
snap-frozen tissues. The person who selected the pa-
tients was blind to patient’s clinical information exceptdiagnosis. Human medulloblastoma cell lines (D283 and
Daoy) were purchased from the American Type Culture
Collection (ATCC, Manassas, VA). D283 cells were cul-
tured in Minimum Essential Medium Eagle (EMEM;
ATCC), and Daoy cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM; Invitrogen, Carlsbad,
CA) supplemented with 10% (v/v) fetal bovine serum
(FBS; Invitrogen) and penicillin-streptomycin (1× final
concentration; Invitrogen). All cells were incubated at
37°C in a 5% CO2/ 95% air atmosphere.
Real-time quantitative polymerase chain reaction (PCR)
The levels of mRNA transcription were assessed by real-
time quantitative PCR (RT-qPCR) using TaqMan probes
(Applied Biosystems, Carlsbad, CA) in an ABI 7000 sys-
tem. TaqMan probes for ID1 (ABI Catalog number
Hs00357821), ID2 (Hs00747379), ID3 (Hs00171409),
ID4 (Hs00155465), and glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH; Hs99999905) were used. The re-
actions were performed under the conditions specified
in the ABI TaqMan Gene Quantitation assay protocol,
and all reactions were repeated in triplets. The compara-
tive threshold cycle (ΔCt) method calculated the relative
gene expression, normalized to GAPDH and relative to
normal brain expression [27].
siRNA and shRNA knockdown of ID3
siRNA and shRNA were used to knock down ID3 ex-
pression in the D283 cell line. Control siRNA (#SN1002)
and ID3-siRNA (#1072358) were designed and synthe-
sized by Bioneer (Daejeon, Korea) for the in vitro studies.
Transfection of the control-siRNA and ID3-siRNA was
performed using Lipofectamine RNAiMax (Invitrogen) fol-
lowing the manufacturer’s instructions. Lentiviral particles
containing shRNA targeting the human ID3 (SHCHLNG-
NM_002167), nontargeting shRNA (SHC002V), and GFP
(SHC003V)-containing control transduction particles were
obtained from Sigma-Aldrich (St. Louis, MO) for in vivo
studies. D283 cells were seeded in 96-well plates and
transduced in 110 μl of EMEM containing 10% FBS
and 8 μg/ml hexadimethrine bromide. The cells were
reseeded in 6-well plates 24 hrs after incubation and se-
lected using 1 μg/ml puromycin for 7 days. Knockdown
efficiency and specificity with siRNA and shRNA was
confirmed using RT-qPCR with the gene expression
normalized to GAPDH. Knockdown of ID gene expres-
sion was further confirmed by western blot.
ID3 rescue experiment
To prove the specificity of the ID3-shRNA knockdown,
full-length ID3 cDNA (360 bp) was synthesized using
the RT–PCR Kit (Clontech, Mountain View, CA) from
RNA extraction of D283 cells. Constructs were inserted
into the BamH1/Xho1cloning site of pEGFP.C2 (BD
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ID3 knockdown D283 cell line using the Neon® Trans-
fection (Invitrogen) according to the manufacturer’s
instructions with some modifications. ID3-shRNA
knockdown cells (1 × 107) were resuspended in 120 μl
of Neon® Resuspension Buffer R with 12 μg of plasmid
DNA pulsed once according to the manufacturer’s in-
structions. After the pulse, cells were quickly trans-
ferred into EMEM media containing 10% FBS. Cells
transfected with a pEGFP.C2 vector were used as a
control. Expression of green fluorescent protein (GFP)
was observed by fluorescence microscopy 24 hrs after
nucleofection. The cells were then incubated for 48 hrs be-
fore RNA and protein collection for further experiments.
Western blot
After Transfection with siRNA negative control or ID3-
siRNA, cells were resuspended in protein extraction so-
lution (Intron Biotech, Seongnam, Korea), according to
the manufacturer’s protocol. Protein concentrations were
determined using BCA protein assay kit (Thermo Fisher
Scientific, Waltham, MA). For immunoblottg, 40 μg of
protein was prepared in SDS sample buffer (Invitrogen),
boiled for 10 min at 70°C and electrophoresed on a 4–
12% gradient bis-Tris gel (Invitrogen). The proteins were
then electotransfered to a polyvinylidene fluoride mem-
brane (Invitrogen) using iblot transfer system (Invitrogen).
After the membrane had been blocked with Tris-buffered
saline (TBS) containing 5% nonfat dry milk, it was incu-
bated overnight at 4°C with the following anti-ID1 anti-
body (1:500; Abnova, Taipei, Taiwan), anti-ID2 antibody
(1:500; Cell Signaling Technology, Danvers, MA), anti-ID3
antibody (1:500; Cell Signaling Technology), anti-ID4 anti-
body (1:250; Abcam, Cambridge, UK) and monoclonal
anti-β-actin antibody (1:10,000; Sigma-Aldrich) in TBS
containing 0.1% Tween-20. After the blot was washed, it
was incubated with horseradish-peroxidase–conjugated
species-specific secondary antibody (1:5,000; Jackson
Laboratory, West Grove, PA) for 1 hr at room
temperature. After the blots had been washed several
times in TBS with 0.1% Tween-20, they were developed
with enhanced chemiluminescence reagent (Invitrogen)
and exposed to Kodak BioMax autoradiography film,
and developed.
Viability assay
D283 cells were transfected with control-siRNA or ID3-
siRNA, seeded in 96-well plates (5 × 103), and incubated
for 48 hrs. CCK (cell counting kit; Dojindo, Kumamoto,
Japan) was added and incubated for 2 hrs. Then, absorb-
ance of each well was measured at 540 nm using a
micro-ELISA reader (Molecular Devices, Sunnyvale,
CA). The percentage of cellular survival was determined
using the relative absorbance of ID3-siRNA-transfectedcells versus control-siRNA-transfected cells. All in vitro
assays were performed in triplicate.
Proliferation assay
The proliferation rates of D283 cells were measured
using a BrdU ELISA kit (Roche Diagnostics, Basel,
Switzerland) 48 hrs after transfection with control- or
ID3-siRNA. The cells were plated in 96-well plates at an
equal density (5 × 103). BrdU was added to the cells for
4 hrs, and the cells were treated according to the manu-
facture’s protocol. The optical density at 450 nm was
measured using an ELISA plate reader.
Apoptosis assay
TUNEL assay was performed for the detection of apop-
totic cells using an ApopTag Peroxidase In situ Apop-
tosis Detection Kit (Chemicon, Temecula, CA). D283
cells were transfected with control- or ID3-siRNA (1 ×
104) and cultured in 2-well chamber slides for 24-48 hrs.
The cells were fixed and stained according to the manu-
facturer’s instructions. Apoptotic cells were observed
and quantified in 5 randomly chosen high-power fields
under a light microscope. The apoptosis index was de-
fined as a percentage of the observed apoptotic cells in
1,000 cells.
Cellular senescence assay
Senescence-associated ß-galactosidase (SA-ß-gal) activity
was detected using the Cellular Senescence Assay Kit
(Chemicon), according to the manufacturer’s instruc-
tions. D283 cells were transfected with control- or ID3-
siRNA (1 × 104), seeded in 6-well plates, and incubated
for 16 hrs at 37°C. Representative microscopic fields
were photographed under a 10× objective lens.
Cell cycle analysis
D283 cells were transfected with control- or ID3-siRNA
(1 × 106) and detached by scraping. The cells were fixed
in 70% iced-cold ethanol with vortexing and incubation
for 1 hr at 20°C. The cells were washed with cold PBS and
resuspended with 0.5 mg/ml Rnase A (Sigma-Aldrich).
After 1 hr at 37°C, 10 μg/ml propidium iodine solution
(Sigma-Aldrich) was added in the dark at 4°C and the cells
were observed with fluorescent microscopy. The cells
were analyzed using fluorescence-activated cell sorting
(FACS).
Migration assay
D283 cells were transfected with control- or ID3-siRNA
prior to seeding onto the upper chamber of a Transwell
(8 μm pore size; Corning Costar, Corning, NY). The cells
(5 × 104/ well) were harvested after transfection and in-
troduced into the upper chamber. The cells in the upper
chamber were maintained in serum-free medium that
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the lower chamber was filled with culture medium
supplemented with 10% fetal bovine serum as the
chemoattractant. The cells without siRNA treatment
were included as reagent control. The remaining cells at
the upper surface were completely removed using a cot-
ton swab after 16 hrs. The migrated cells on the lower
surfaces of the membranes were fixed and stained in a
solution of 1% (w/v) crystal violet in 2% ethanol for
30 seconds and rinsed in distilled water. The migrated
cells were quantified in 5 randomly chosen fields. The
assays were performed in triplicate.
mRNA miniarray for 94 genes related to cellular invasion
and migration
The mRNA expression of 94 cellular invasion and migra-
tion gene was analyzed using a ready-to-use Array Human
Extracellular Matrix & Adhesion Molecules 96-well Plate
(Applied Biosystems; Catalog number, 4414133) and the
ABI 7500 Real-Time qPCR system. Selected genes that
demonstrated large discrepancies were confirmed using
RT-PCR. The primer sequences and PCR parameters are
summarized in Additional file 1: Table S1.
Reverse transcriptase polymerase chain reaction
Total RNA was isolated from human tissues and tumor
cell lines using a PureLink RNA mini-kit (Invitrogen).
cDNA synthesis was performed using EcoDry Premix-
Random hexamers (Clontech, Madison, WI), following
the manufacturer’s instructions. PCR amplification was
performed using AccuPower PCR premix (Bioneer). The
primer sequences and PCR parameters are summarized
in Additional file 1: Table S1. The PCR products were
resolved on a 1% agarose gel stained with ethidium
bromide and visualized using a UV transilluminator.
Immunohistochemistry
Four paraffin-embedded medulloblastoma tissues (2 tissues
from patients with seeding and 2 tissues from patients
without seeding) were sectioned at 4 μm using a micro-
tome and transferred to silane-coated slides. Immunohisto-
chemistry was performed as described previously [28].
Primary antibodies and their concentrations were applied
as follows: ID3 (1:50; Spring Bioscience, Pleasanton, CA),
tissue inhibitor of metalloproteinase 3 (TIMP3; 1:100;
Novus Biologicals, Littleton, CO), integrin beta 4 (ITGB4;
1:50; Abcam), collagen type XII alpha1 (COL12A1;
1:1; Abnova), ADAM metallopeptidase with thrombos-
pondin type 1 motif 8 (ADAMTS8; 1:100; Abbiotec, San
Diego, CA), tenascin C (TNC; 1:100; Abcam), connective
tissue growth factor (CTGF; 1:600; Abcam), and intercellu-
lar adhesion molecule 1 (ICAM1; 1:25; Cell Signaling
Technology).Animal model and inhibition of tumor seeding in vivo
The Institutional Animal Care and Use Committee of
Seoul National University College of Medicine approved all
animal experiment protocols. Transplantation of cells into
female BALB/cnude mice was performed under aseptic
conditions. D283 cells were labeled using fluorescent mag-
netic nanoparticle (LEO-LiveTM-675; Biterials, Seoul,
Korea) for live in vivo imaging or chloromethylbenzamido-
DiI (Molecular Probes, Eugene, OR) for Immunofluores-
cence staining. The cells were washed three times after a
24-hour incubation and suspended in PBS at a concentra-
tion of 1.5 × 106 cells per 30 μl. Mice were anesthetized
using an intraperitoneal injection of 100 mg/kg ketamine
(Yuhan, Seoul, Korea) and 10 mg/kg xylazine (Bayer Korea,
Seoul, Korea). The mouse heads were fixed in a stereo-
tactic guiding device (David Kopf Instruments, Tujunga,
CA), and the cisterna magna was exposed under a
microscopic view. Labeled cells were slowly injected
into the subarachnoid space of the cisterna magna using
a 30-gauge needle [29].
Live in vivo image acquisition and analysis were
performed using an in vivo multispectral imaging system
(CRi Maestro™ In-Vivo Imaging System; Cri, Hopkinton,
MA). The injected cells were observed using an in vivo
multispectral imaging system every 3–4 days. The re-
gions of interest (ROI) were drawn over the tumor and
normal tissue, and the average signal (×106 photons/
cm2 × s) for each area was measured.
The longitudinal length from the cranial to caudal
ends of the signal was measured to evaluate the extent
of seeding. The mice were perfused with 4% paraformal-
dehyde under deep anesthesia and sacrificed 30 days
after cellular implantation. Whole brains and spinal
cords were fixed and dehydrated in graded sucrose
concentrations. The tissues were embedded in OCT
compound (Tissue-Tek®; Sakura, Tokyo, Japan) and
stored at −80°C. The brains were sectioned sagittally
into 10 μm-thick slices using a cryostat. Spinal cords
were sectioned in 5-μm intervals beginning at the
cervicomedullary junction. The sections were stained
with hematoxylin and eosin.
Immunofluorescence staining was further performed on
the sections to confirm the presence of proliferating and
apoptotic cells. Sectioned tissues were washed and the pri-
mary antibodies were applied. Primary antibodies used
were anti-ID2 antibody (1:100; Cell Signaling Technology),
anti-ID3 antibody (1:200; Cell Signaling Technology),
anti-ID4 antibody (1:50; Abcam), and anti-Ki-67 nuclear
antigen (1:400; Abcam) for proliferating cell staining, anti-
caspase-3 (1:200; Cell Signaling Technology) for apoptotic
cell staining, and anti-human nuclei (1:250; Millipore,
Billerica, MA). Alexa Fluor 488 or 594-conjugated goat
anti-rabbit or mouse immunoglobulin-G (IgG) (1:200;
Invitrogen) were used for secondary antibodies. After
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solution containing 4′-6-diamidino-2-phenylindole (DAPI;
Vector Laboratories, Burlingame, CA) and negative con-
trol staining were established by omitting the primary
antibodies. The apoptotic and proliferating indices were
defined as the percentage of positive nuclei within the
total number of nuclei in three random fields. The sec-
tions were observed using a confocal microscope (Carl
Zeiss, Oberkochen, Germany).
Review of patient clinical data
The electronic medical records (EMR) of selected pa-
tients were reviewed retrospectively. All patients re-
ceived initial surgical resection at the Seoul National
University Children’s Hospital from Nov. 1998 to Apr.
2009. Clinical data included the patient’s age at diagno-
sis, sex, tumor histology, and tumor seeding at presenta-
tion. Patient survival was confirmed from follow-up
sheets in the EMR. Tumor progression was defined as
radiological documentation of a new tumor or the
growth of preexisting masses (> 25% in 2-D analyses).
All patients were followed up from the time of initial
surgery (initial diagnosis) until the date of death or until
Jan 29, 2013, whichever occurred first. Death certificate
information was retrieved from the National Statistical
Office and the Ministry of Public Administration and Se-
curity. A structured data extraction form was developed
in which clinical data from the EMR was merged with
the death certificate information and experimental data
(i.e., the expression levels of specific genes).
Identification of molecular subgroup of tumors
Medulloblastomas are heterogeneous tumors consisting
of at least 4 distinct molecular subgroups [13]. Tumor
tissues from 31 patients out of the 39 patients compris-
ing this study were also included in a large-scale gen-
omic study of Dr. Taylor MD, in which subgroup
affiliation was performed using a nanoString-based RNA
assay [30]. The information of subgroup allocations were
obtained for 30 patients and the tumors were divided
into WNT, SHH, Group 3, and Group 4 medulloblas-
toma (information courtesy of Dr. Taylor MD).
Statistical analyses
A Mann–Whitney U test or Student t test were applied
to compare continuous variables between 2 groups. Ana-
lysis of variance (ANOVA) was used for comparison of
data between 3 groups. Progression-free survival (PFS)
was defined as the time interval from the day of initial
surgery to the date that tumor progression was docu-
mented radiologically or the date of the last follow-up.
Overall survival (OS) was defined as the time interval
from the day of initial surgery to the date the patient
died or the date of the last follow-up. We explored thebest cutoff point of ID3 for predicting occurrence of
death or progression of MB using receiver operator
characteristic (ROC) analyses without considering the
length of follow-up. Since the value of 6.007 was optimal
for both outcomes, a high expression level of ID3 was
defined as a greater than 6.007-fold increase in mRNA
expression in RT-qPCR normalized to controls. Survival
in each group was analyzed using a Kaplan-Meier
method. A log-rank test was used for comparisons of
survival data between groups. Multivariate analyses of
PFS and OS were conducted using the Cox proportional
hazard model. Clinical variables with a P value less than
0.1 in univariate analyses were included in the multivari-
ate models. Basic clinical variables such as sex and age
at diagnosis were included in multivariate analyses re-
gardless of their P values. All tests were two-sided, and a
P value less than 0.05 was considered significant.
MedCalc version 12.4.0 (MedCalc, Ostend, Belgium; a
free-trial version) was used for ROC analysis and IBM-
SPSS version 19.0 software (IBM, Armonk, NY) was
used for all the other statistical analyses.
Results
Expression of ID genes in human medulloblastoma
The mRNA expression of ID genes (ID1, ID2, ID3, and
ID4) was assessed in human medulloblastoma tissues
using RT-qPCR (N = 39 for ID3 and N = 37 for ID1, ID2,
and ID4). The average expression levels for ID1, ID2,
and ID4 in medulloblastoma were lower than the ex-
pression levels in normal cerebellum. There were strong
positive correlations between ID1 and ID4 (Pearson co-
efficient r = 0.381, P = 0.020), and between ID2 and ID4
(r = 0.460, P = 0.004). However, there was no significant
correlation between ID3 and other ID genes.
No significant difference between seeding-negative and
seeding-positive groups was observed for ID1, ID2, and
ID4 (P = 0.724 for ID1, P = 0.890 for ID2, and P = 0.854
for ID4; Mann–Whitney u-test) (Figure 1A, B, D). In con-
trast, the seeding-positive group (N = 18) demonstrated
significantly higher ID3 transcript levels than the seeding-
negative group (N = 21) (53.6 ± 78.3 vs. 6.2 ± 7.6 in folds
difference; P = 0.007; Mann–Whitney U test; Figure 1C).
ID3 mRNA expression was compared in medulloblastoma
cell lines, Daoy and D283. Higher ID3 mRNA expression
was observed in D283 than in Daoy (data not shown).
Knockdown efficiency and specificity of ID3-siRNA and
ID3-shRNA
A stable and specific knockdown of ID3 transcripts of
greater than 50% for 48 hrs was confirmed after ID3-
siRNA transfection to D283 cells (Figure 2A). ID1, ID2,
and ID4 transcripts were not decreased by ID3-
knockdown (Figure 2B). Decrease of ID3 protein expres-
sion was also confirmed by western blot (Figure 2C).
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P = 0.854
Figure 1 Expression of ID genes in medulloblastoma. (A-D) RT-qPCR results of ID1, ID2, ID3, and ID4 in 37-39 medulloblastoma tissues
dichotomized into seeding (+) and seeding (−) tumors. Horizontal bars represent the average values. ID3 transcript levels were significantly
different between the groups.
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ID3-shRNA) or control-shRNA (D283-control-shRNA)
were constructed for in vivo experiments. ID3 transcript
levels in RT-qPCR decreased significantly after selection
with puromycin (P = 0.003; Student t-test; Figure 2D).
Transfection with ID3-shRNA resulted in decrease of
ID1, ID2, and ID3 transcripts and increase of ID4 tran-
script, but only ID3 showed greater than 50% reduction of
transcript level compared with the D283-control-shRNA
(Figure 2E). Upon rescue of ID3 expression by pEGFP-
ID3 vector, both ID2 and ID3 transcript levels were re-
stored and ID4 transcript level was normalized. In protein
levels, ID1 expression was not altered either by ID3-
shRNA or by ID3 rescue (Figure 2F). ID2 expression was
slightly decreased by ID3-shRNA but was restored upon
ID3 rescue. ID3 showed dramatic changes of protein ex-
pression, closely following the changes of transcript levels.
Basal ID4 protein expression was negligible in D283 cells.
It showed an increase by ID3-shRNA and a decrease by
ID3 rescue, reflecting the changes of transcript levels.
In vitro assays of D283 cells after transfection with ID3-
siRNA
ID3 knockdown with siRNA significantly decreased cell
viability and proliferation of D283 cells. Cell viabilityafter ID3-siRNA transfection was 54.1 ± 4.6% of the con-
trols (P = 0.002; Student t-test; Figure 3A). The percentage
of BrdU-incorporating cells after ID3-siRNA transfection
was 36.5 ± 3.2% of the controls, indicating decreased pro-
liferation (P < 0.001; Student t-test; Figure 3B).
The impact of ID3 knockdown on cellular apoptosis
and senescence was assessed in D283 cells because ID3
knockdown decreased cellular viability. A TUNEL assay
revealed a significant increase in apoptosis in ID3-
siRNA-transfected cells compared with controls (6.0 ±
0.5% vs. 2.6 ± 0.2%; P < 0.001; Student t-test; Figure 3C
and D). No significant difference in SA-ß-gal activity be-
tween these groups was observed (3.6 ± 0.4%, vs. 3.0 ±
0.4%; P = 0.174; Student t-test), which indicated that ID3
did not influence cellular senescence (Figure 3E).
Cell cycles in D283 cells transfected with ID3-siRNA
and controls were compared. Cell cycle analyses using
FACS revealed a significant decrease in the fraction in
the G1 phase and an increase in the fractions in G2 and
sub-G1 phases after ID3-siRNA transfection compared
with controls (G1 phase: 66.4 ± 2.2% vs. 51.4 ± 2.0%,
P = 0.002; G2 phase: 6.3 ± 1.2% vs. 16.4 ± 2.2%, P = 0.039;
S phase: 26.1 ± 1.1% vs. 34.0 ± 2.5%, P = 0.076; Sub-G1
phase: 2.4 ± 1.0% vs. 11.8 ± 2.6%, P = 0.046; Student t-test;




















































































Figure 2 Knockdown efficiency and specificity of ID3-siRNA and ID3-shRNA. (A) ID3 knockdown greater than 50% for 48 hrs was confirmed
after ID3-siRNA transfection to D283 cells. (B) ID3 showed a selective reduction of the transcript level after ID3-siRNA treatment. (C) Western blot
confirmed specific knockdown of ID3 with siRNA. (D) D283 cell lines transfected with ID3-shRNA (D283-ID3-shRNA) showed a significant
reduction of ID3 mRNA after puromycin selection. (E) After transfection with ID3-shRNA, ID1, ID2, and ID3 transcripts levels were decreased and
ID4 level was significantly increased. Upon ID3 rescue, ID2 and ID3 transcript levels were restored and ID4 level was also normalized. (F) In protein
expression, there was a minimal decrease of ID2 expression by ID3-shRNA. The basal ID4 protein expression was negligible in D283 cells. ID4 also
showed significant changes in opposite directions of ID3, as indicated in transcript levels.
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results are consistent with previous experiments on cellu-
lar proliferation and apoptosis.
The in vitro migration ability of D283 cells
transfected with ID3-siRNA was compared with that of
controls to assess the influence of ID3 gene on medul-
loblastoma seeding. ID3 knockdown significantly re-
duced the migration of D283 cells in a transwell
migration assay (P < 0.001; Student t-test; Figure 3H
and I).
In vivo migration of D283 cells after ID3-siRNA or ID3-
shRNA transfection
A medulloblastoma seeding model was created using
nude mice. Diffuse spinal leptomeningeal seeding of
tumor cells was confirmed 4 weeks after D283 cell injec-
tion into the cisterna magna. The in vivo seeding
capability of D283-ID3-shRNA was compared with
D283-control-shRNA in this model.
Live in vivo imaging of the mice injected with only
PBS (N = 3) or with D283-control-shRNA (N = 7) re-
vealed an enlargement of tumor masses at the injectionsite for 21 days and seeding along the spinal cord
thereafter. In contrast, the mice injected with D283-
ID3-shRNA (N = 6) exhibited stable tumor mass sizes
at the injection site and no seeding along the spinal
cord (Figure 4A). A significant difference in the total
areas of optical signal between the groups (D283-control-
shRNA vs. D283-ID3-shRNA) was observed (P = 0.028;
ANOVA; Figure 4B). The longitudinal length of the op-
tical signals from the cranium to the spinal canal was also
significantly different between groups (P < 0.001; ANOVA;
Figure 4C).
Grossly, the mice injected with D283-control-shRNA
exhibited cachexia, poor hygiene, and scoliosis, which
indicated the spinal seeding of tumor cells; mice
injected with D283-ID3-shRNA were generally healthy
(Figure 4D). A Kaplan-Meier survival curve demon-
strated a significant decrease in the survival of mice
injected with D283-control-shRNA compared with
mice that received D283-ID3-shRNA (P = 0.047; log-
rank test; Figure 4E).
Postmortem histological examination revealed huge





























































































































Figure 3 In vito cellular effects of ID3 knockdown by siRNA in D283 cells. (A) Cellular viability was assessed using CCK assays. There was a
significant reduction of cell viability (B) Cell proliferation was significantly decreased, assessed using BrdU assays. (C) Apoptosis was assessed using
TUNEL staining (40×). (D) Quantification of TUNEL-positive cells revealed a significant increase of apoptosis after siRNA treatment. (E) There was
no difference in senescence, assessed using β-gal staining. (F and G) Cell cycle analysis using FACS showed that G2 phase and sub-G1 fractions
were increased after siRNA treatment. Migratory ability was assessed using transwell migration assays. (H) Representative field images (100×) and
(I) the quantification of migrated cells revealed suppression of cell migration by ID3-siRNA. Error bars represent standard deviations.
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http://www.biomedcentral.com/1471-2407/13/291leptomeningeal seeding of tumor cells in mice injected
with D283-control-shRNA, but tumor cells were
scarcely observed in mice that received D283-ID3-
shRNA (Figure 5A and B). Immunofluorescence stain-
ing revealed that abundant Ki-67+ tumor cells were
observed in control mice, but mice injected with D283-
ID3-shRNA had few Ki-67+ tumor cells (11.29 ± 3.67% in
D283-control-shRNA vs. 6.00 ± 2.89% in D283-ID3-shRNA;
P = 0.004; Student t-test; Figure 5C, F, I). On the contrary,
abundant caspase-3-expressing tumor cells were ob-
served in mice injected with D283-ID3-shRNA (1.67 ±
1.23% in D283-control-shRNA vs. 14.58 ± 3.80% in
D283-ID3-shRNA; P < 0.001; Student t-test; Figure 5D,
G, J). ID3 expression was effectively suppressed in mice
that received D283-ID3-shRNA (Figure 5E and H). No
difference of ID2 expression between the groups was
observed and anti-ID4 fluorescence signal was too weak
to detect in both groups (data not shown).Expression of cellular invasion and migration genes after
ID3-siRNA transfection in D283 cells
Sixty-six cellular invasion and migration genes were
detectable in D283 cells using the mRNA miniarray.
Thirteen genes [(TIMP3, collagen type VI alpha 2
(COL6A2), thrombospondin 1 (THBS1), COL12A1,
matrix metallopeptidase 14 (MMP14), ITGB4, collagen
type V alpha 1 (COL5A1), collagen type I alpha 1
(COL1A1), ADAMTS8, selectin L (SELL), laminin alpha
3 (LAMA3), collagen type VII alpha 1 (COL7A1), collagen
type VIII alpha 1 (COL8A1)] were upregulated, and 3
genes (TNC, CTGF, ICAM1) were downregulated more
than 2-fold after ID3 knockdown in D283 cells in vitro
(Figure 6A). Stably transcribed genes were selected by
discarding genes without amplification peaks at 35 cycles
in RT-qPCR processes. Four upregulated genes (TIMP3,
ITGB4, COL12A1, ADAMTS8) and 3 downregulated
genes (TNC, CTGF, ICAM1) were associated with ID3
Control-shRNA ID3-shRNA






























































Figure 4 ID3 knockdown by shRNA and inhibition of tumor seeding in vivo. (A) Representative live in vivo imaging of implanted D283 cells
transfected with either control-shRNA or ID3-shRNA for 28 days. Note the migration of signals along the spinal cord of a mouse injected with
D283-control-shRNA. (B) Serial measurement of tumor-occupied areas in live in vivo imaging. (C) Serial measurement of the longitudinal extent of
tumors from the cranium to the spinal canal. (D) Representative gross photos of mice injected with PBS, D283-controlshRNA, and D283-ID3-shRNA.
Mice that received D283-control-shRNA (middle photo) show cachexia and scoliosis, signs of tumor seeding along the spinal cord. (E) A Kaplan-Meier
survival plot of mice after implantation of D283 cells reveals the increased survival by shRNA. All animals were sacrificed at day 28 for histological
examination.
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http://www.biomedcentral.com/1471-2407/13/291knockdown. These results were confirmed using RT-PCR
(Figure 6B). Immunohistochemistry of ID3, TIMP3,
ITGB4, COL12A1, ADAMTS8, TNC, CTGF, and ICAM1
in human medulloblastoma tissues demonstrated different
protein expression patterns according to the seeding sta-
tus of the disease. A higher expression of TIMP3, ITGB4,
COL12A1, and ADAMTS8 was observed in the seeding-
negative group, and a higher expression of ID3 and CTGF
was observed in the seeding-positive tumors. There were
slightly stronger expression of TNC and ICAM1 in the
seeding-positive tumors, but the immunopositive areas
were restricted to tumor stroma rather than tumor cell
clusters where the majority of ID3-immunoreactivity was
found (Figure 6C).Molecular subgroup of tumors
The molecular subgroups of 30 tumors were identified:
WNT subgroup (2 tumors), SHH subgroup (8 tumors),
Group 3 (6 tumors), and Group 4 (14 tumors). ID3 tran-
script levels in RT-qPCR of these subgroups were com-
pared. Group 4 tumors showed significantly higher
levels of ID3 mRNA than other subgroups (P = 0.029;
Mann–Whitney U test; Figure 7A). Important clinical
profiles of the patients in each subgroup were summa-
rized in Figure 7B. Age at diagnosis less than 3 yrs was
mainly observed in SHH subgroup and Group 3 showed
highest rate of anaplastic histology. In Group 4, there
was no patient with young-age-onset less than 3 yrs and
only 1 patient had an anaplastic medulloblastoma.
Control-shRNA
































































Figure 5 Histological section of mice for evaluation of tumor seeding. (A and B) Representative longitudinal sections of the brains and
spinal cords of the mice with D283-control-shRNA or D283-ID3-shRNA (hematoxylin & eosin stain) (1.25×). Inlet figures denote (a) subfrontal area,
(b) craniocervical junction (cistern magna) where the tumor cells were first implanted, (c) upper thoracic spinal cord, (d) midthoracic spinal cord,
(e) lumbar spinal cord, and (f) conus medullaris (100×). (C and F) Immunofluorescence (IF) staining with anti-Ki-67, a proliferation marker, on the
specimen. (D and G) IF staining with anti-caspase-3, an apoptosis marker. Scale bars represent100 μm. (E and H) IF staining with anti-ID3. (I and J)
Comparison of the proportions of Ki-67+ cells and caspase-3+ cells.
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http://www.biomedcentral.com/1471-2407/13/291Survival of medulloblastoma patients according to ID3
expression
The survival of patients with medulloblastoma in whom
ID3 expression levels were assessed using RT-qPCR was
analyzed. During the follow-up, 22 patients (56%) ex-
pired and 17 patients (44%) were censored. Because of
the wide range of ID3 expression levels in patients with
tumor seeding, ID3 expression levels were dichotomized
into high and low expression levels (> 6.007-fold differ-
ence vs. ≤ 6.007-fold difference, respectively) relative to
the expression level of normal cerebellum. A total of 17
patients were placed in the high ID3-expression group,
and 22 patients exhibited low ID3 expression. The clin-
ical characteristics of each group are summarized in
Table 1. Only seeding at presentation were significantly
more frequent in the high ID3-expression group than in
the low ID3-expression group (P = 0.01), all the other
prognostic factors did not show any statistical difference
between the high and low ID3 expression groups.
Kaplan-Meier curves demonstrated that the high ID3-expression group had marginally significantly shorter
PFS than the low ID3-expression group (P = 0.086; log-
rank test; Figure 8A). The high ID3- expression group
also had significantly shorter OS than the low ID3-
expression group (P = 0.025; log-rank test; Figure 8B).
Multivariate analyses revealed that high-ID3 expression
was an independent risk factor of death in patients with
medulloblastoma after the adjustment of major prognos-
tic factors (P = 0.034, aHR = 3.840, 95% CI = 1.107 -
13.312). The risk for progression of medulloblastoma by
the high expression of ID3 was 2.137 times (95% CI: =
0.684 - 6.676), which was not statistically significant after
the adjustment (P = 0.192) (Table 2). Age younger than 3
yrs old at the diagnosis, seeding at presentation, anaplas-
tic histology were statistically significant risk factors for
both outcomes, however, residual tumor larger than
1.5 cm2 was not significant after the adjustment.
In the patients with Group 4 tumors (N = 14), detailed
analysis of risk factor was not indicated because of the
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> 2 folds up-regulated genes > 2 folds down-regulated genes
Figure 6 mRNA mini-array to uncover ID3-related genes. (A) Expression of 66 genes related to cellular invasion and metastasis after ID3
knockdown using siRNA in D283 cells. (B) RT-PCR of ID3 and the 7 genes with considerable initial expression levels and expression level changes
of greater than 2-fold. (C) Representative images of immunohistochemistry of ID3 and 7 proteins in seeding-negative and seeding- positive
medulloblastomas (200×). Note that TNC is mainly expressed in the tumor stroma (arrow) than tumor cell clusters where ID3 immunoreactivity
is observed.
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http://www.biomedcentral.com/1471-2407/13/291age younger than 3 yrs and anaplastic histology were far
less represented in this subgroup, high ID3 expression
may have more impact than the whole patient cohort.
High ID3-expression group (N = 6) had significantly
shorter PFS and OS than the low ID3-expression group
(P = 0.021 and P = 0.040, respectively; log-rank test;
Figure 8C and D).
Discussion
ID genes are known as transcriptional repressors and
have important roles in developmental processes. There
are four ID gene homologues, ID1, ID2, ID3, and ID4 in
human and other vertebrates [19]. The functions of ID
genes must be redundant and depend on the cellular
context to some degree. Knockout of either ID1 or ID3
alone in mice generated apparently normal phenotypes
[31]. There are also functional interactions between ID
genes. ID3-shRNA used for this experiment showed a
significant on-target effect on ID4 (down-regulation)and a minimal influence on ID2 expression. It is known
that ID3 can down-regulate ID4 in a specific cellular
context [32]. Furthermore, in medulloblastoma tissues
and cell lines examined (D283 and Daoy), basal ID4
transcript level and protein expression was negligible
compared with those of ID3. Therefore, we focused on
the functional role of ID3 in medulloblastoma.
Overexpression of ID genes is widely reported in hu-
man cancers, including cancers of gastrointestinal tract,
breast, prostate, endometrium, cervix, and thyroid, to
name a few [19]. Their expression is further regarded as
poor prognostic factor in some of the cancers [33]. ID1,
ID2, and ID3 are known to regulate cell fate determin-
ation and to maintain undifferentiated states [19]. There-
fore, they can keep tumor cells in stem-cell-like states or
cause dedifferentiation (anaplasia). Actually, ID1 has
been proposed as a marker of glioma-initiating cells
[34]. ID genes can promote cell proliferation and pre-
vent apoptosis, the two key properties of cancer cells.
AB
ID3















Figure 7 Molecular subgroup of medulloblastoma and ID3. (A) ID3 expression assessed with RT-qPCR according to the medulloblastoma
subgroups (N = 30). (B) Clinical characteristics (young age at diagnosis < 3 yrs, seeding at presentation, and anaplastic histology) of patients in
each subgroup.
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http://www.biomedcentral.com/1471-2407/13/291Knockdown experiments of ID genes in various cancer
cell lines showed decreased proliferation and enhanced
apoptosis in vitro. One of the most crucial actions of ID
genes is their involvement in cell migration, invasion,
and angiogenesis which makes ID genes promote metas-
tasis. Knockdown of ID1 and ID3 inhibited metastatic po-
tentials of esophageal and pancreatic cancers in vitro and
in vivo [25,35]. Inhibition of metastasis-suppressing genes
and promotion of epithelial-mesenchymal transition have
been proposed as the mechanisms of action [36,37].
Medulloblastoma is characterized by high rates of
tumor seeding through the neuraxis which occurs atTable 1 Comparison of clinical characteristics between
high ID3-expressing and low ID3-expressing groups
ID3-expressing group
Characteristics Low (N = 22) % High (N = 17) %
Mean age (± SD; yrs) 3.63 (± 3.42) 4.70 (± 4.06)
Sex (male) 15 68.2 12 70.6
Age at diagnosis (<3 yrs) 4 18.2 4 23.5
Residual tumor (> 1.5 cm2) 2 9.1 1 5.9
Seeding at presentation 6 27.3 12 70.6
Anaplastic histology 4 18.2 0 0
SD = standard deviation.both early and terminal stages of the disease. Tumor
seeding at presentation is a strong predictor of poor out-
come in medulloblastoma [8]. Tumor seeding also af-
fects long-term quality of life of survivors, because many
clinical protocols on medulloblastoma mandate more
intensified treatment for a disseminated disease than a
localized tumor. Recently, genomic characteristics of
medulloblastoma are being unveiled and the molecular
classification demonstrates that the disease consists of at
least 4 distinct subgroups [12,13]. In this context, key
genetic players and molecular mechanisms of medullo-
blastoma seeding are arousing much interest [17].
In the present study, we explored whether ID genes
are associated with medulloblastoma seeding. The tran-
script level of ID3 was much higher in medulloblastomas
than in normal cerebellum, and was also independent of
other ID genes. Furthermore, ID3 transcripts were dif-
ferentially elevated in seeding-positive medulloblastomas
than in seeding-negative tumors. Considering the gen-
eral functions of ID genes in many human cancers, we
postulated that ID3 may be a potential player in medul-
loblastoma seeding.
Knockdown of ID3 in the medulloblastoma cell line
resulted in decrease of cell viability and proliferation, en-
hanced apoptosis, and suppressed migratory activities
in vitro. A study showed that ID1 and ID3 facilitated
High ID3-expression (N = 17)
Low ID3 - expression (N = 22)
High ID3- expression (N = 17)
Low ID3 - expression (N = 22)
P = 0.086 P = 0.025
[ Whole patient cohort (N = 39) ] [ Whole patient cohort (N = 39) ]
A B
High ID3 - expression (N = 6)
Low ID3 - expression (N = 8)
High ID3- expression (N = 6)
Low ID3 - expression (N = 8)
P = 0.021 P = 0.040
[ Patients with Group 4 tumors (N = 14) ] [ Patients with Group 4 tumors (N = 14) ]
C D
Figure 8 Patient survival according to ID3 expression levels. (A and B) Kaplan-Meier survival curves for progression-free survival (PFS) and
overall survival (OS) in 39 patients with medulloblastoma. Fold changes greater than 6.007 in RT-qPCR was considered as high ID3-expression.
(C and D) Survival plots for PFS and OS in 14 patients who had Group 4 medulloblastomas.
Table 2 Relative risks for shorter progression-free survival (PFS) and overall survival (OS) estimated with Cox
proportional hazard models
Crude HR 95% Hazard ratio confidence interval Adjusted HR 95% Hazard ratio confidence interval
PFS
Sex 1.383 0.571 3.349 0.745 0.276 2.012
Age at diagnosis (<3 yrs) 2.558 0.989 6.617 4.612 1.527 13.927
Residual tumor (> 1.5 cm2) 27.303 4.299 173.409 5.990 0.681 52.719
Seeding at presentation 3.871 1.663 9.008 3.546 1.142 11.014
Anaplastic histology 3.254 1.086 9.748 8.229 1.465 46.242
High ID3 expression 2.018 0.887 4.595 2.137 0.684 6.676
OS
Sex 2.043 0.747 5.585 1.286 0.428 3.863
Age at diagnosis (<3 yrs) 2.195 0.780 6.179 4.323 1.249 14.959
Residual tumor (> 1.5 cm2) 4.374 1.225 15.619 0.680 0.120 3.834
Seeding at presentation 4.734 1.881 11.914 3.373 1.113 10.222
Anaplastic histology 3.200 1.056 9.691 13.235 2.058 85.090
High ID3 expression 2.609 1.090 6.249 3.840 1.107 13.312
Phi et al. BMC Cancer 2013, 13:291 Page 13 of 16
http://www.biomedcentral.com/1471-2407/13/291
Phi et al. BMC Cancer 2013, 13:291 Page 14 of 16
http://www.biomedcentral.com/1471-2407/13/291sustained proliferation during the early stages of meta-
static colonization of breast carcinoma [26]. This finding
indicates that not only increased migration/ invasion
capability but also enhanced survival at the remote sites
may contribute to the metastasis-promoting action of ID
genes. Therefore, the association of ID3 with medullo-
blastoma seeding may depend on these pleiotropic func-
tions of ID3 gene. In vivo study of ours reinforced this
concept. In the animal seeding model of medulloblas-
toma, stable knockdown of ID3 in injected tumor cells
lead to a decreased extent of tumor seeding and
prolonged survival of mice. The tumor masses formed in
the primary injection were also much smaller than con-
trols. On histological examination, a scattered thin layer of
tumor cells was observed on the spinal leptomeninges,
but the tumor cells lacked proliferative activities and
showed high proportion of apoptosis. From these findings,
ID3 could be viewed better as an indicator of disease ag-
gressiveness rather than simply as a metastasis-promoting
factor.
Many genes must be involved in the multiple actions
of ID3 in establishment of metastasis. Through a small
array system and tumor cell line, we found several can-
didate genes of ID3 targets. The most intriguing genes
may be TNC and CTGF that showed downregulation
after ID3 knockdown. TNC is a candidate oncongene re-
sponsible for disease progression of ependymomas [38].
There is a report that TNC protein and its partner
integrins mediate adhesion of medulloblastoma cells to
leptomeninges and facilitate tumor seeding [39]. How-
ever, in our study, the protein expression of TNC was
generally limited to the tumor stroma, apart from tumor
cell clusters where most of ID3 immunoreactivity was
observed. Therefore, the cross-talk between tumor cells
and microenvironment needs further elucidation. CTGF
is known to be a member of Musachi1-associated gene
network which is highly expressed in aggressive medul-
loblastoma [40]. Although the mRNA expression of
thrombospondin-1 (THBS1) was not augmented in
D283 cells in our experiment, THBS1 was upregulated
after silencing of ID3. A previous study demonstrated
that downregulation of THBS1 was strongly associated
with MYC-driven metastatic phenotype of medulloblas-
toma [17].
In the RT-qPCR results of ID genes (Figure 1), ID3
transcript levels were not uniformly elevated in the
seeding-positive group, but only a small number of tu-
mors showed high expression of ID3. This finding may
indicate that medulloblastomas have diverse seeding
mechanisms and ID3 may represent one of the machin-
ery that acts in a limited group of patients. In the prog-
nostic analyses using the patients’ clinical data, high
ID3-expression was an independent negative prognostic
factor, but it was associated only with OS, withoutsignificantly affecting PFS. Traditional risk factors such
as young age at diagnosis (< 3 yrs), seeding at presenta-
tion, and anaplastic histology all significantly influenced
both PFS and OS in the whole patient cohort. However,
it should be noted that the confidence intervals of haz-
ard ratios are rather wide, indicating that they are based
on a small number of patients and events.
It is well established that medulloblastomas are het-
erogeneous tumors in which molecular classification is
possible. Therefore, we obtained information on the sub-
group allocations and compared ID3 expression between
the subgroups. Although the allocated numbers are
small in each subgroup, their clinical characteristics were
consistent with the published data [12,13]: young age at
diagnosis (< 3 yrs) in SHH subgroup, high proportions
of seeding at presentation and anaplastic histology in
Group 3, and relatively low proportions of young age at
diagnosis (no patient) and anaplastic histology (only 1
patient) in Group 4. Interestingly, Group 4 medulloblas-
tomas showed significantly higher ID3 expression than
other subgroups. This finding may have intriguing impli-
cations. In the current molecular classification, Group
3 tumors are associated with anaplastic histology, MYC
amplification, metastatic phenotype, and dismal prog-
nosis. Experimentally, high MYC expression induces
metastatic tumors in orthotopic medulloblastoma
models [17].
Group 4 medulloblastomas have a higher proportion
of seeding at presentation than WNT and SHH sub-
groups, but MYC amplification and anaplasia are seldom
found in the subgroup [13]. We can postulate that these
medulloblastoma subgroups have distinct mechanisms
of tumor seeding driven by different genes. Therefore,
ID3 may represent the metastatic/ aggressive phenotype
of Group 4 medulloblastomas that lack MYC amplifica-
tion. Survival analyses of patients with Group 4 tumors
reinforced this assumption. In Group 4 tumors, high
ID3 expression may have greater prognostic impact be-
cause these tumors have higher ID3 expression than
other subgroups, and because young age at diagnosis
and anaplastic histology, the two robust risk factors were
virtually excluded from this group (0 and 1 patient each).
Despite the small number of patients with Group 4 tu-
mors (N = 14), high ID3-expression was more repre-
sented as a poor prognostic factor in this subgroup,
significantly affecting both PFS and OS.
Conclusion
High ID3 expression was associated with medulloblas-
toma seeding at presentation, but not all tumors with
seeding had high ID3 expression. Silencing of ID3 in
D283 cell line decreased proliferation, increased apop-
tosis, and suppressed migration in vitro. In vivo knock-
down experiment demonstrated that ID3 not only
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http://www.biomedcentral.com/1471-2407/13/291increased migration capability, but also enhanced sur-
vival at the metastatic loci of medulloblastoma cells. In
survival analysis of the patients, high ID3 expressions
emerged as a poor prognostic factor, especially in pa-
tients with Group 4 medulloblastomas. ID3 may repre-
sent the metastatic/aggressive phenotype of Group 4
medulloblastomas.
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